Drug profile · INN
epoetin alfa
EPOSTIM
epoetin alfa (EPOSTIM) is a erythropoietin receptor agonist. Route of administration: single-use. Current US regulatory status: approved.
Drug details — epoetin alfa
- US status
- approved
- Class
- Blood and blood forming organs (B03)
- Route
- SINGLE-USE
- Patents
- 0
- Programs
- 4
- Data quality
- 0.84
Quick answer
epoetin alfa (EPOSTIM) is a erythropoietin receptor agonist. Route of administration: single-use. Current US regulatory status: approved.
Key facts
Mechanism of action
Erythropoietin receptor agonist
Primary target: Erythropoietin receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is epoetin alfa?
epoetin alfa (EPOSTIM) is a erythropoietin receptor agonist. Route of administration: single-use. Current US regulatory status: approved.
What is the brand name for epoetin alfa?
EPOSTIM is a marketed brand name for epoetin alfa. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of epoetin alfa?
epoetin alfa has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.